Valeant Pharmaceuticals Buys Specialty Pharma

Aliso Viejo-based Valeant Pharmaceuticals said Wednesday that it has signed a definitive agreement to acquire Coria Laboratories, a specialty pharmaceutical company focused on dermatology. Valeant said it will pay approximately $95M for Coria, from parent firm DFB Pharmaceuticals and other shareholders. Valeant Pharmaceuticals said that Coria currently has annualized net sales of approximately $40M.